VERA THERAPEUTICS INC. - CLASS A COMMON STOCK

Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results

11 май 2023 07:30:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

04 май 2023 08:00:01 Источник Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

28 мар 2023 07:30:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

27 фев 2023 16:05:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock

06 фев 2023 16:05:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

01 фев 2023 21:51:59 Источник Nasdaq GlobeNewswire

Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock

01 фев 2023 16:01:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria

30 янв 2023 06:00:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)

25 янв 2023 08:00:01 Источник Nasdaq GlobeNewswire

Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

03 янв 2023 16:01:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

20 дек 2022 16:05:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics to Present at Upcoming Investor Conferences

22 ноя 2022 07:30:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP

17 ноя 2022 07:30:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

09 ноя 2022 07:30:01 Источник Nasdaq GlobeNewswire

Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney Week 2022 Annual Meeting

05 ноя 2022 16:50:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2022 Annual Meeting

17 окт 2022 07:30:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics to Present at Upcoming Conferences in September 2022

07 сен 2022 07:30:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

10 авг 2022 07:30:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

04 авг 2022 07:30:01 Источник Nasdaq GlobeNewswire

Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

06 июл 2022 07:30:00 Источник Nasdaq GlobeNewswire